- Global Pharma News & Resources

Kezar Life Sciences to Participate in Three Upcoming Investor Conferences

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and oncologic disorders, today announced that Christopher Kirk, PhD, Co-founder, President and Chief Scientific Officer, will participate in three upcoming investor conferences in September.

Presentation Details:

Event: 2022 Wells Fargo Healthcare Conference
Location: Boston, MA
Date/Time: Thursday, September 8, 2022, at 1:20 PM ET
Format: Fireside Chat

Event: H.C. Wainwright 24th Annual Global Investment Conference
Location: New York, NY
Date/Time: Tuesday, September 13, 2022, at 11:30 AM ET
Format: Podium Presentation

Event: Morgan Stanley 20th Annual Global Healthcare Conference
Location: New York, NY
Date/Time: Wednesday, September 14, 2022, at 9:10 AM ET
Format: Fireside Chat

Webcasts from the presentations will be available on the “Events & Presentations” section of the Company’s website at Following the events, archived webcasts will be available on the Kezar website for 90 days.

About Kezar Life Sciences

Kezar Life Sciences is a clinical-stage biopharmaceutical company discovering and developing breakthrough treatments for immune-mediated and oncologic disorders. The company is pioneering first-in-class, small-molecule therapies that harness master regulators of cellular function to inhibit multiple drivers of disease via single, powerful targets. Zetomipzomib, its lead development asset, is a selective immunoproteasome inhibitor being evaluated in a Phase 2 clinical trial in lupus nephritis. This product candidate also has the potential to address multiple chronic immune-mediated diseases. KZR-261 is the first anti-cancer clinical candidate from the company’s platform targeting the Sec61 translocon and the protein secretion pathway. An open-label dose-escalation Phase 1 clinical trial of KZR-261 to assess safety, tolerability and preliminary tumor activity in solid tumors is underway. For more information, visit


Investor Contact

Gitanjali Jain
Vice President, Investor Relations and External Affairs

Media Contact

Liza Sullivan
Argot Partners

Editor Details

  • Company:
    • Businesswire
Last Updated: 01-Sep-2022